A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously UntreatedChronic Lymphocytic Leukemia

The purpose of study is to compare the effectiveness of two combinations of anticancer study drugs in treating your chronic lymphocytic leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. Sonrotoclax and zanubrutinib are investigational drugs developed by BeiGene (the sponsor). Sonrotoclax has not been approved for treatment by the United States Food and Drug Administration (FDA). Zanubrutinib has been approved for the treatment of certain blood cancers by the FDA. However, it is still considered experimental because it is not approved in the United States for treating patients as a combination therapy with Sonrotoclax.

Are you Eligible? (Inclusion Criteria)

• Age 18 years or older 2. Are you able to sign the informed consent and able to comply with the study protocol in the investigator’s judgment. 3.Have an estimated life expectancy of 6 months or greater